Skip to main content

Advertisement

SpringerLink
Log in

A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

The urokinase plasminogen activator(uPA) system plays important roles in tumor cell invasion and metastasis. In the present study, we evaluated the effects of ATF-PAI2CD, a hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2, on 95D cells in vitro and in vivo. Furthermore, our results support a current hypothesis that fusion protein blocks tumor invasion and motility by inhibiting localized pericellular proteolysis. Treatment of 95D cells with ATF-PAI2CD resulted in a dose-dependent decrease in tumor-cell invasion through matrigel, and ATF-PAI2CD was much more effective than PAI-2CD. In addition, extracellular regular protein kinase (ERK1/2) expression was downregulated and the adhesion ability to fibronectin was increased in 95D cells treated with the fusion protein, which was confirmed by cell adhesion assay. A high-concentration of ATF-PAI2CD caused a significant reduction in tumor volume and weight in BALB/c (nu/nu) mice female inoculated with human 95D cells (5×106); the antitumor effects were significant, which demonstrated a 67.9±4.2% reduction in tumor growth compared with control mice. The number of lymphatic metastasis was significantly reduced in mice treated with high- and middle- concentrations of ATF-PAI2CD, whereas a low-concentration of ATF-PAI2CD failed to exhibit any antimetastatic effects. In conclusion, the results suggested that the hybrid protein has therapeutic potential for lung carcinoma and other tumors to inhibit tumor invasion and metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1–22

    Article  PubMed  Google Scholar 

  2. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572

    Google Scholar 

  3. Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22:205–222

    Article  CAS  PubMed  Google Scholar 

  4. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activator system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25–40

    Article  CAS  PubMed  Google Scholar 

  5. Wang Y (2001) The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 21:146–170

    Article  PubMed  Google Scholar 

  6. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K (1991) Cellular receptor for urokinase plasminogen activator. Carboxyl- terminal processing and membrane anchoring by glycosyl- phosphatidylinositol. J Biol Chem 266:1926–1933

    CAS  PubMed  Google Scholar 

  7. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Dano K (1991) The ligand-binding domain of the cell surface receptor for urokinase- type plasminogen activator. J Biol Chem 266:7842–7847

    CAS  PubMed  Google Scholar 

  8. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380–32388

    CAS  PubMed  Google Scholar 

  9. Schmitt M, Wilhelm OG, Reuning U, Kruger A, Harbeck N, Lengyel E, Magdolen V (2000) The urokinase plasminogen activator system as a novel target for tumor therapy. Fibrinolysis 14:114–132

    Article  CAS  Google Scholar 

  10. He C, He P, Liu LP, Zhu YS (2001) Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells. J Cancer Res Clin Oncol 127:180–186

    Article  CAS  PubMed  Google Scholar 

  11. Liao JH, Xu SH, Tang HB, Lian FZ, Zhu YS (2001) Antisense RNA for urokinase receptor inhibits the invasiveness and metastasis of lung carcinoma. Chin J Pathol 30:357–360

    CAS  Google Scholar 

  12. Tian Y, Shen JQ, Li P, Zhu YS (2000) The protection function of the PAI-2 from TNF-α is dependent upon its protein binding domain. Acta Biochim Biophys Sincia 32:175–178

    CAS  Google Scholar 

  13. Dickinson JL, Norris BJ, Jensen PH, Antalis TM (1998) The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis. Cell Death Differ 5:163–171

    Article  CAS  PubMed  Google Scholar 

  14. Ballance DJ, Marshall JM, Cottingham IR, Steven J, Berry SJ, Cederholm-Williams SA, Goodey AR, Courtney M (1992) A hybrid protein of urokinase growth-factor domain and plasminogen- activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor. Eur J Biochem 207:177–183

    CAS  PubMed  Google Scholar 

  15. Xu SH, Liao JH, Zhu YS (2000) Inhibition of invasiveness of human breast cancer cells by antisense RNA for urokinase receptor. Chin J Biochem Mol Biol 16:814–819

    CAS  Google Scholar 

  16. Tian Y, Shen JQ, Li P, Song HY, Zhu YS (2000) Biochemical characterization of PAI-2 and its mutants. Acta Biochim Biophys Sincia 32:126–132

    CAS  Google Scholar 

  17. Wang X, Li P, Zhang YQ, Hou M, Sun XH, Tan L, Zhu YS (2003) Biological function of fusion protein ATF-PAI2CD. Acta Biochim Biophys Sincia 35:624–628

    CAS  Google Scholar 

  18. Wang X, Hou M, Sun XH, Li P, Zhang YQ, Tan L, Zhu YS () Construction and expression of human ATF-PAI-2CD fused gene. Chin J Biochem Mol Biol Revised

  19. Busk M, Pytela R, Sheppard D (1992) Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. J Biol Chem 267:5790–5796

    CAS  PubMed  Google Scholar 

  20. Hall DE, Neugebauer KM, Reichardt LF (1987) Embryonic neural retinal cell response to extracellular matrix proteins: developmental changes and effects of the cell substratum attachment antibody (CSAT). J Cell Biol 104:623–634

    Article  CAS  PubMed  Google Scholar 

  21. Kobayashi H, Moniwa N, Gotoh J, Sugimura M, Terao T (1994) Role of activated protein C in facilitating basement membrane invasion by tumor cells. Cancer Res 54:261–267

    CAS  PubMed  Google Scholar 

  22. Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932–943

    Google Scholar 

  23. Cox G, Steward WP, O’Byrne KJ (1999) The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax 54:169–179

    CAS  PubMed  Google Scholar 

  24. Mazar AP (2001) The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 12:387–400

    Article  CAS  PubMed  Google Scholar 

  25. Shinkfield MNF, Burnand KG, Balance DJ, Zitka M, Eastham D (1992) The effect of recombinant plasminogen activator inhibitor 2(PAI-2) on the growth of a human tumor cell line in vitro and in vivo. Fibrinolysis 6 [Suppl 4]:59–65

  26. Praus M, Wauterickx K, Collen D, Gerard RD (1999) Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther 6:227–236

    Article  CAS  PubMed  Google Scholar 

  27. Evans DM, Lin PL (1995) Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surg 61:692–697

    CAS  PubMed  Google Scholar 

  28. Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T (1994) Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 71:474–480

    CAS  PubMed  Google Scholar 

  29. Rabbani SA, Gladu J (2002) Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 62:2390-2397

    CAS  PubMed  Google Scholar 

  30. Guo Y, Mazar AP, Lebrun JJ, Rabbani SA (2002) An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res 62:4678–4684

    CAS  PubMed  Google Scholar 

  31. Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA (2000) A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 14:1400–1410

    Article  CAS  PubMed  Google Scholar 

  32. Ploug M, Ostergaard S, Gardsvoll H, Kovalski K, Holst-Hansen C, Holm A, Ossowski L, Dano K (2001) Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40:12157–12168

    Article  CAS  PubMed  Google Scholar 

  33. Billstrom A, Lecander I, Astedt B (1994) Recombinant PAI-2 inhibition of uPA producing tumors in SCID mice. Fibrinolysis 8 [Suppl 1]:56

  34. Akiyama SK, Olden K, Yamada KM (1995) Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 14:173–189

    CAS  PubMed  Google Scholar 

  35. Ruoslahti E (1997) Integrins as signaling molecules and targets for tumor therapy. Kidney Int 51:1413–1417

    CAS  PubMed  Google Scholar 

  36. Boudreau N, Bissell MJ (1998) Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol 10:640–646

    Article  CAS  PubMed  Google Scholar 

  37. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ (2003) Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 60:781–791

    Article  Google Scholar 

  38. Akamatsu H, Ichihara-Tanaka K, Ozono K, Kamiike W, Matsuda H, Sekiguchi K (1996) Suppression of transformed phenotypes of human fibrosarcoma cells by overexpression of recombinant fibronectin. Cancer Res 56:4541–4546

    CAS  PubMed  Google Scholar 

  39. Urtreger A, Porro F, Puricelli L, Werbajh S, Baralle FE, Joffe EBK, Kornblihtt AR, Muro AF (1998) Expression of RGD minus fibronectin that does not form extracellular matrix fibrils is sufficient to decrease tumor metastasis. Int J Cancer 78:233–241

    Article  CAS  PubMed  Google Scholar 

  40. Ma Z, Webb DJ, Jo M, Gonias SL (2001) Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 114:3387–3396

    CAS  PubMed  Google Scholar 

  41. Nguyen DH, Hussaini IM, Gonias SL (1998) Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273:8502–8507

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement.

The work was supported by a grant from the National Natural Science Foundation of China (No. 30170398).

Author information

Authors and Affiliations

  1. Department of Molecular Genetics, Shanghai Medical School, Fudan University, 200032, Shanghai, P.R. China

    Xia Wang, Min Hou, Li Tan, Xinghui Sun, Yuqing Zhang, Ping Li & Yunsong Zhu

Authors
  1. Xia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xinghui Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuqing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yunsong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yunsong Zhu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, X., Hou, M., Tan, L. et al. A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis. J Cancer Res Clin Oncol 131, 129–136 (2005). https://doi.org/10.1007/s00432-004-0623-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-004-0623-2

Keywords

Search

Navigation